Pacira BioSciences, Inc. (PCRX)

Market Cap	876.37M
Revenue (ttm)	694.96M
Net Income (ttm)	-90.73M
Shares Out	46.17M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	7.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,807,508
Open	19.07
Previous Close	19.57
Day's Range	18.73 - 19.80
52-Week Range	11.16 - 35.95
Beta	0.80
Analysts	Buy
Price Target	26.60 (+40.15%)
Earnings Date	Nov 6, 2024

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and sup...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 712
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Financial Performance

In 2023, Pacira BioSciences's revenue was $674.98 million, an increase of 1.22% compared to the previous year's $666.82 million. Earnings were $41.96 million, an increase of 163.72%.

Analyst Forecast

According to 10 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price forecast is $26.6, which is an increase of 40.15% from the latest price.

Price Target

$26.6

(40.15% upside)

Analyst Consensus: Buy